Key result
Vaccination with recombinant murine astrovirus capsid spike protein induced robust anti-spike IgG antibodies in mice, and its crystal structure revealed conserved folding topology with human astrovirus spikes.
Why the study?
Human astrovirus pathogenesis studies and vaccine development are challenging due to the lack of an animal model, motivating the establishment of an in vivo system to test astrovirus capsid spike-based vaccines.
The structural characterization and confirmed immunogenicity of the recombinant MuAstV spike protein lay the foundation for testing astrovirus spike-based vaccines in a murine model.
Answers are grounded in this paper and cite their sources.
Preclinical murine data only; leaves open whether conserved spike topology can guide human astrovirus vaccine strategies.
Human astroviruses (HAstVs) are small, non-enveloped icosahedral RNA viruses that are a significant cause of diarrhoea in young children. Despite their worldwide prevalence, HAstV pathogenesis studies and vaccine development remain challenging due to the lack of an animal model for HAstV infection. The recent development of a murine astrovirus (MuAstV) infection model in mice provides the opportunity to test proof-of-concept vaccines based on MuAstV antigens. To help establish a system in which an astrovirus capsid spike-based vaccine could be tested in vivo , we designed and produced a recombinant MuAstV capsid spike protein based on predicted secondary structure homology to HAstV spike proteins. The recombinant MuAstV spike can be expressed with high efficiency in Escherichia coli and retains antigenicity to polyclonal antibodies elicited by MuAstV infection. We determined the crystal structure of the MuAstV spike to 1.75 Å and assessed its structural conservation with HAstV capsid spike. Despite low sequence identity between the MuAstV and HAstV spikes and differences in their overall shapes, they share related structural folds. Additionally, we found that vaccination with MuAstV spike induced anti-MuAstV-spike antibodies, highlighting that the recombinant spike is immunogenic. These studies lay a foundation for future in vivo MuAstV challenge studies to test whether MuAstV spike can be the basis of an effective vaccine.
No takes yet. Share an insight, caveat, or question.
Lanning et al. (2023) studied Murine astrovirus infection. Recombinant MuAstV capsid spike protein vs. Naïve mice was evaluated on Induction of anti-MuAstV spike IgG antibodies and crystal structure determination. Vaccination with recombinant murine astrovirus capsid spike protein induced robust anti-spike IgG antibodies in mice, and its crystal structure revealed conserved folding topology with human astrovirus spikes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: